Subgroup analyses presented at the 66th American Society of Hematology Annual Meeting and Exposition in San Diego support the clinical benefit of brentuximab vedotin (Adcetris; Pfizer) in heavily pretreated patients with relapsed or refractory diffuse large B-cell lymphoma. Read More ›
